ADULT HIV CARE

Appendix B: Prognosis According to CD4 Cell Count and Viral Load in the Pre-HAART and HAART ErasB

Click to enlarge: Reprinted with permission from Elsevier (The Lancet, 2002, Vol. 360, 19-29).

Click to enlarge: Reprinted with permission from Elsevier (The Lancet, 2002, Vol. 360, 19-29).

 

Selecting an Initial ART Regimen

June 2016

Editor’s Note: This section is currently under revision. Please refer to the DHHS guideline What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient for the most current information on preferred initial ART regimens, alternative initial ART regimens, considerations for prescribing initial ART in the setting of specific clinical scenarios, and advantages and disadvantages of antiretroviral components recommended as initial ART.

Appendix C: FDA Pregnancy Categories

Category A: Adequate and well-controlled studies of pregnant women fail to demonstrate a risk to the fetus during the first trimester of pregnancy (and there is no evidence of risk during later trimesters).

Category B. Animal reproduction studies fail to demonstrate a risk to the fetus and adequate and well-controlled studies of pregnant women have not been conducted.

Category C. Animal reproduction studies fail to demonstrate a risk to the fetus and adequate and well-controlled studies of pregnant women have not been conducted.

Category D. Positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experiences, but the potential benefits from the use of the drug in pregnant women may be acceptable despite its potential risks.

Category X. Studies in animals or reports of adverse reactions have indicated that the risk associated with the use of the drug for pregnant women clearly outweighs any possible benefit.